Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 469-480 , August 2009

Respiratory manifestations of systemic lupus erythematosus: old and new concepts

  • José María Pego-Reigosa, MD, PhD, Consultant Rhumatologist, Doctor

      Affiliations

    • Rheumatology Section, Hospital do Meixoeiro (Complexo Hospitalario Universitario de Vigo), Alto do Meixoeiro s/n, 36200 Vigo (Pontevedra), Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 986229912; Fax: +34 986811169.
    • ,
  • Dina A. Medeiros, MD, Doctor

      Affiliations

    • Rheumatology Department, Portuguese Institute of Rheumatology, R Beneficência 7, 1050-034 Lisbon, Portugal
    • ,
  • David A. Isenberg, MD, FRCP, Professor of Rheumatology

      Affiliations

    • Centre for Rheumatology Research, University College of London Division of Medicine, Room 331, 3rd Floor, The Windeyer Building, 46 Cleveland Street, London, W1T 4JF, UK

References 

  1. Weinrib L, Sharma OP, Quismorio FP. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum. 1990;20:48–56
  2. Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med. 1981;71:791–798
  3. Matthay RA, Schwarz MI, Petty TL, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore). 1975;54:397–409
  4. Travis WD, King TE, Bateman ED. ATS/ERS Consensus statement of idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;265:277–304
  5. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44:585–596
  6. Cheema GS, Quismorio FP. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med. 2000;6:424–429
  7. Inoue T, Kanayama Y, Ohe A, et al. Immunopathologic studies of pneumonitis in systemic lupus erythematosus. Ann Intern Med. 1979;91:30–34
  8. Good JT, King TE, Antony VB, Sahn SA. Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest. 1983;84:714–718
  9. Pines A, Kaplinsky N, Olchovsky D, et al. Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications. Chest. 1985;88:129–135
  10. Pertschuk LP, Moccia LF, Rosen Y, et al. Acute pulmonary complications in systemic lupus erythematosus. Immunofluorescence and light microscopic study. Am J Clin Pathol. 1977;68:553–557
  11. Zamora M, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival, and outcome. Medicine. 1997;76:192–202
  12. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest. 2000;118:1083–1090
  13. Erickson RW, Franklin WA, Emlen W. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum. 1994;24:114–123
  14. Rojas-Serrano J, Pedroza J, Regalado J, et al. High prevalence of infections in patients with systemic lupus erythematosus and pulmonary haemorrhage. Lupus. 2008;17:295–299
  15. Hatano S, Strasser T. World Health Organization 1975 primary pulmonary hypertension. Geneve: WHO; 1975;
  16. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus. 2000;9:338–342
  17. Shen JY, Chen SL, Wu YX, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int. 1999;18:147–151
  18. Kasparian A, Floros A, Gialafos E, et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus. 2007;16:505–508
  19. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465–1472
  20. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243–2278
  21. Fayemi AO. Pulmonary vascular disease in systemic lupus erythematosus. Am J Clin Pathol. 1976;65:284–290
  22. Quismorio FP, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum. 1984;13:349–359
  23. Chung SM, Lee CK, Lee EY, et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol. 2006;25:866–872
  24. Robbins IM, Gaine SP, Schilz R, et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000;117:14–18
  25. Mok MY, Tsang PL, Lam YM, et al. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus. 2007;16:279–285
  26. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441–447
  27. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292–1297
  28. González-Lopez L, Cardona-Muñoz EG, Celis A, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus. 2004;13:105–112
  29. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension. A retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521–531
  30. Abramson SB, Dobro J, Eberle MA, et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med. 1991;114:941–947
  31. Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum. 1994;37:376–383
  32. Gladman DD, Urowitz MB. Venous syndromes and pulmonary embolism in systemic lupus erythematosus. Ann Rheum Dis. 1980;39:340–343
  33. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990;112:682–698
  34. Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol. 1990;17:1292–1298
  35. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050–1057
  36. Hoffbrand BI, Beck ER. ‘Unexplained’ dyspnoea and shrinking lungs in systemic lupus erythematosus. BMJ. 1965;1:1273–1277
  37. Bertoli AM, Vila LM, Apte M, et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus. 2007;16:410–417
  38. Traynor AE, Corbridge TC, Eagan AE, et al. Prevalence and reversibility of pulmonary dysfunction in refractory systemic lupus: improvement correlates with disease remission following hematopoietic stem cell transplantation. Chest. 2005;127:1680–1689
  39. Toya SP, Tzelepis GE. Association of the Shrinking Lung Syndrome in Systemic Lupus Erythematosus with Pleurisy: A Systematic Review. Semin Arthritis Rheum. 2008 Jun 26;[Epub ahead of print]
  40. Gibson CJ, Edmonds JP, Hughes GR. Diaphragm function and lung involvement in systemic lupus erythematosus. Am J Med. 1977;63:926–932
  41. Martens J, Demedts M, Vanmeenen MT, Dequeker J. Respiratory muscle dysfunction in systemic lupus erythematosus. Chest. 1983;84:170–175
  42. Laroche CM, Mulvey DA, Hawkins PN, et al. Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus. Q J Med. 1989;71:429–439
  43. Van Veen S, Peeters AJ, Sterk PJ, Breedveld FC. The ‘shrinking lung syndrome’ in SLE, treatment with theophylline. Clin Rheumatol. 1993;12:462–465
  44. Muñoz-Rodríguez FJ, Font J, Badia JR, et al. Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy. Lupus. 1997;6:412–414
  45. Langford CA, Waes C. Upper airway obstruction in the rheumatic diseases: life-threatening complications of autoimmune disease. Rheum Dis Clin North Am. 1997;23:345–363
  46. Teitel AD, MacKenzie CR, Stern R, Paget SA. Laryngeal involvement in systemic lupus erythematosus. Semin Arthritis Rheum. 1992;22:203–214
  47. Thong BY, Thumboo J, Howe HS, Feng PH. Life-threatening angioedema in systemic lupus erythematosus. Lupus. 2001;10:304–308
  48. Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol. 1996;166:301–307
  49. Andonopoulos AP, Constantopoulos SH, Galanopoulou V, et al. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest. 1988;94:312–315
  50. Keane MP, Lynch . Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax. 2000;55:159–166
  51. Andonopoulos AP. Adult respiratory distress syndrome: an unrecognized premortem event in systemic lupus erythematosus. Br J Rheumatol. 1991;30:346–348
  52. Kim WU, Kim SI, Yoo WH, et al. Adult respiratory distress syndrome in systemic lupus erythematosus: causes and prognostic factors: a single center, retrospective study. Lupus. 1999;8:552–557
  53. Begum S, Li C, Wedderburn LR, et al. Concurrence of sarcoidosis and systemic lupus erythematosus in three patients. Clin Exp Rheumatol. 2002;20:549–552
  54. Hunter T, Arnott JE, McCarthy DS. Features of systemic lupus erythematosus and sarcoidosis occurring together. Arthritis Rheum. 1980;23:364–366
  55. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154:1851–1856
  56. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4:723–730
  57. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 1996;39:1951–1960
  58. Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis. 1986;133:321–340
  59. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005;38:473–485
  60. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550–2557
  61. Kinder BW, Freemer MM, King TE, et al. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum. 2007;56:2679–2686
  62. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Practice Res Clin Rheumatol. 2002;16:281–291
  63. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am. 1998;24:423–456
  64. O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus. 2006;15:778–783
  65. Li J, Huang XM, Fang WG, et al. Pneumocystis carinii in patients with connective tissue disease. J Clin Rheumatol. 2006;12:114–117
  66. Bin J, Bernatsky S, Gordon C, et al. Lung cancer in systemic lupus erythematosus. Lung Cancer. 2007;56:303–306
  67. Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2008;67:74–79
  68. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–369
  69. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35:248–254

PII: S1521-6942(09)00003-5

doi: 10.1016/j.berh.2009.01.002

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 469-480 , August 2009

Article Tools

* Image Usage & Resolution